CEL-SCI Corporation (CVM)

Market Cap	102.79M
Revenue (ttm)	n/a
Net Income (ttm)	-36.87M
Shares Out	43.74M
EPS (ttm)	-0.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	61,080
Open	2.26
Previous Close	2.24
Day's Range	2.26 - 2.38
52-Week Range	1.88 - 6.14
Beta	1.71
Analysts	Buy
Price Target	10.71 (+356.72%)
Earnings Date	Feb 14, 2023

About CVM

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 1, 1987
• Employees: 43
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: CVM

Analyst Forecast

According to 5 analysts, the average rating for CVM stock is "Buy." The 12-month stock price forecast is $10.71, which is an increase of 356.72% from the latest price.

Price Target

$10.71

(356.72% upside)

Analyst Consensus: Buy